Drug therapy in cardiogenic shock.
D002302:Cardiac Output / Q000187:drug effects; D004071:Digitalis Glycosides / Q000494:pharmacology / Q000627:therapeutic use; D004298:Dopamine / Q000494:pharmacology / Q000627:therapeutic use; D005934:Glucagon / Q000494:pharmacology / Q000627:therapeutic use; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007545:Isoproterenol / Q000494:pharmacology / Q000627:therapeutic use; D009921:Metaproterenol / Q000494:pharmacology / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology; D009638:Norepinephrine / Q000494:pharmacology / Q000627:therapeutic use; D010646:Phentolamine / Q000494:pharmacology / Q000627:therapeutic use; D010952:Plasma Substitutes / Q000627:therapeutic use; D012770:Shock, Cardiogenic / Q000150:complications / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D013148:Spironolactone / Q000494:pharmacology / Q000627:therapeutic use
D004071:Digitalis Glycosides; D010952:Plasma Substitutes; D013148:Spironolactone; D009921:Metaproterenol; D005934:Glucagon; D007545:Isoproterenol; D004298:Dopamine; D009638:Norepinephrine; D010646:Phentolamine